Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671710 · ClinicalTrials.gov registry record · Phase 1
Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
A Phase 1 study, sponsored by Advocate Hospital System.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00671710 is a Phase 1 study that has completed, run by Advocate Hospital System. The registered enrollment target is 26 participants.
The verdict
NCT00671710, a Phase 1 study, has completed, sponsored by Advocate Hospital System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Tumors of the central nervous system are potentially curable. For tumors of comparable histology and grade, resectability is the most important prognostic factor affecting survival particularly in children. However, the infiltrative nature of the malignant cells produces indistinct borders between normal and malignant tissues, and the lack of easily identifiable tumor margins confounds attempts toward total resection. The investigators propose to identify the borders of tumors intraoperatively using protoporphyrin fluorescence of the malignant cells and thereby provide more complete tumor resection.
Interventions
- DRUG Aminolevulinic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671710
The ClinicalTrials.gov registry entry for NCT00671710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advocate Hospital System, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aminolevulinic Acid is the first listed.
NCT00671710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671710 about?
NCT00671710 is a clinical study titled "Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain". Tumors of the central nervous system are potentially curable. For tumors of comparable histology and grade, resectability is the most important prognostic factor affecting survival particularly in children. However, the infiltrative nature of the malignant cells produces indistinct borders between n...
What is the current status of trial NCT00671710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00671710?
The interventions under investigation include: Aminolevulinic Acid (DRUG).
Who is sponsoring clinical trial NCT00671710?
This trial is sponsored by Advocate Hospital System, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.